Clinical observation of influences of donor HBV infection on allogeneic hematopoietic stem cell transplantation recipients
10.7652/jdyxb201802028
- VernacularTitle:供者HBV感染对异基因造血干细胞移植受者的影响
- Author:
Xiao-Ning WANG
1
;
Jian-Na YAO
;
Chun-Hong SUN
;
Cai-Li GUO
;
Jie-Ying XI
;
Peng-Cheng HE
;
Mei ZHANG
Author Information
1. 西安交通大学第一附属医院血液内科
- Keywords:
allogeneic hematopoietic stem cell transplantation;
HBV infection;
hematopoietic reconstitution;
hepatic veno-occlusive disease
- From:
Journal of Xi'an Jiaotong University(Medical Sciences)
2018;39(2):296-298
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influences of donor HBV infection on allogeneic hematopoietic stem cell transplantation recipients.Methods We made a retrospective analysis of data of four patients without HBV infection who underwent allogeneic hematopoietic stem cell transplantation from January 2015 to December 2016. Among them donors of these patients all had HBV infection.We then observed the influences of HBV infection on hematopoietic reconstruction,hepatic vein occlusive disease and HBV infection.Results HBV serological conditions of two donors were HbsAb,HbeAb and HbcAb positive,and quantitative of HBV-DNA was negative;the donor and the recipient did not use anti-HBV drugs.One donor was HbsAg,HbeAb and HbcAb positive,and the quantitative of HBV-DNA was also positive.Another donor was HbsAg and HbcAb positive,and the quantitative of HBV-DNA was also positive.These two donors received oral nucleoside therapy one month before stem cell collection and the recipients of these two donors also took nucleoside drugs one week before the conditioning.Hepatitis B immune globulin was given after transfusion of stem cells and the third day and seventh day after transplantation.Quantitative of HbsAb was detected each month and if it was less than 150 IU,hepatitis B immune globulin would be given.All the recipients had hematopoietic reconstruction and no VOD or hepatitis B virus infection occurred.Conclusion Oral administration of nucleoside drugs combined with hepatitis B immunoglobulin can effectively prevent HBV infection in recipients with HBV infection donors.
